ReviewCurrent nutrition reports2026
Precision Microbiome Modulation: Exploring Lactobacillus spp. as A Targeted Strategy for Type 2 Diabetes Management.
Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe International Diabetes Federation projects a prevalence of 783.2 million cases of type 2 diabetes mellitus (T2DM) by 2045. The escalation in healthcare expenditure and adverse effects of current drugs necessitate a clinically effective and low-cost alternative therapeutic option with minimal health complications. Lactobacillus spp., a well-studied gut probiotic has shown promising antidiabetic effects against T2DM in several randomized controlled trials. However, the exact mechanisms of Lactobacillus spp. in regulating the glycaemic profile are not well elucidated, limiting the optimization of probiotic-based interventions. Therefore, this paper aims to explore the various antidiabetic mechanisms of Lactobacillus spp., with a focus on their integration into precision medicine approaches. RECENT
findingsLactobacillus spp. supplementation alleviates insulin resistance in T2DM by modulating glucose metabolism and transport, exerting anti-inflammatory and anti-oxidative effects as well as restructuring gut microbiota. Lactobacillus spp. also enhance the functional properties of food by increasing the antioxidant capacity and improving glucose metabolism. Despite these promising effects, clinical translation is challenged by strain-specific survivability in the gastrointestinal tract and safety concerns. Thus, leveraging precision medicine via tailoring treatments based on individual microbiome profiles, genetic backgrounds and metabolic phenotype may unravel the full therapeutic potential of targeted Lactobacillus spp. for T2DM treatment. This approach can be reached by integrating multi-omics profiling and artificial intelligence technologies. Lactobacillus spp. may act as adjunctive support in the management T2DM rather than stand-alone therapies in T2DM management, as their efficacy is dependent on appropriate dietary interventions and metabolic context. Altogether, integrating Lactobacillus spp. into personalized treatment frameworks offers a promising avenue for developing more targeted, effective and safe interventions for T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.